Skip to content
HowShorted

Anika Therapeutics Inc. short interest in 2023

In 2023, Anika Therapeutics Inc.'s disclosed short interest ran from 3.72% of shares outstanding on 13 Jan 2023 to 3.68% on 29 Dec 2023, a change of -0.04 percentage points. The year's high was 6.64% on 15 Sep 2023 and its low 2.59% on 30 Jun 2023, averaging 3.54% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.14 days on 31 Jan 2023. Full history: Anika Therapeutics Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Anika Therapeutics Inc. in 2023

2023 in figures

Start of year
3.72% (13 Jan 2023)
End of year
3.68% (29 Dec 2023)
Change
-0.04 pp
High
6.64% (15 Sep 2023)
Low
2.59% (30 Jun 2023)
Average
3.54%
Highest days to cover
8.14 (31 Jan 2023)
SEC filings marked
8

Every report in 2023

Anika Therapeutics Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20233.72%6.65
31 Jan 20233.45%8.14
15 Feb 20233.51%7.89
28 Feb 20233.62%7.40
15 Mar 20233.19%3.87results (8-K)
31 Mar 20233.16%5.5910-K filed
14 Apr 20233.15%6.93
28 Apr 20232.96%6.16
15 May 20233.07%6.1610-Q filed, results (8-K)
31 May 20233.14%7.13
15 Jun 20233.14%7.23
30 Jun 20232.59%3.07
14 Jul 20232.95%5.52
31 Jul 20233.35%6.08
15 Aug 20234.08%4.7010-Q filed, results (8-K)
31 Aug 20235.46%6.56
15 Sep 20236.64%1.50
29 Sep 20232.98%2.31
13 Oct 20233.20%4.29
31 Oct 20233.61%5.25
15 Nov 20233.34%4.46results (8-K), 10-Q filed
30 Nov 20233.57%4.38
15 Dec 20233.44%6.88
29 Dec 20233.68%8.08

See also: Anika Therapeutics Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.